Evolution of substance use, neurological and psychiatric symptoms in schizophrenia and substance use disorder patients: A 12-week, pilot, case-control trial with quetiapine

Frontiers in Psychiatry

Volumn 2, Issue MAY, 2011, Pages

  Zhornitsky, Simon ^a   Stip, Emmanuel ^a   Desfossés, Joelle ^a   Pampoulova, Tania ^a,b   Rizkallah, Élie ^a,b   Rompré, Pierre Paul ^a   Bentaleb, Lahcen Aït ^a   Lipp, Olivier ^a   Chiasson, Jean Pierre ^b   Gendron, Alain ^c   Potvin, Stéphane ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b Clinique du Nouveau Depart   (Canada)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Akathisia; Cannabis; Paranoia; Quetiapine; Schizophrenia; Substance use disorder

Indexed keywords

QUETIAPINE;

ADULT; AKATHISIA; ARTICLE; BARNES AKATHISIA SCALE; CALGARY DEPRESSION SCALE; CANNABIS ADDICTION; CASE CONTROL STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM RATING SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PILOT STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOLOGICAL RATING SCALE; SCHIZOPHRENIA; SUBSTANCE ABUSE; SYMPTOM; UNSPECIFIED SIDE EFFECT;

EID: 84862904302     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2011.00022     Document Type: Article

References (60)

1. Abi-Dargham, A., Gil, R., Krystal, J., Baldwin, R. M., Seibyl, J. P., Bowers, M., van Dyck, C. H., Charney, D. S., Innis, R. B., and Laruelle, M. (1998). Increased striatal dopamine transmission in schizophre-nia: confirmation in a second cohort. Am. J. Psychiatry 155, 761-767.
2. Addington, D., Addington, J., and Maticka- Tyndale, E. (1993). Assessing depres-sion in schizophrenia: the Calgary Depression Scale. Br. J. Psychiatry Suppl. 22, 39-44.
3. Addington, J., and Addington, D. (1997). Substance abuse and cognitive func-tioning in schizophrenia. J. Psychiatry Neurosci. 22, 99-104.
4. Arvanitis, L. A., and Miller, B. G. (1997). Multiple fixed doses of " Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a com-parison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol. Psychiatry 42, 233-246.
5. Aubin, G., Stip, E., Gélinas, I., Rainville, C., and Chapparo, C. (2009). Daily activities, cognition and commu-nity functioning in persons with schizophrenia. Schizophr. Res. 107, 313-318.
6. Bandelow, B., Chouinard, G., Bobes, J., Ahokas, A., Eggens, I., Liu, S., and Eriksson, H. (2010). Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int. J. Neuropsychopharmacol. 13, 305-320.
7. Barnes, T. R. (1989). A rating scale for drug-induced akathisia. Br. J. Psychiatry 154, 672-676.
8. Bersani, G., Gherardelli, S., Clemente, R., Di Giannantonio, M., Grilli, A., Conti, C. M., Exton, M. S., Conti, P., Doyle, R., and Pancheri, P. (2005). Neurologic soft signs in schizophrenic patients treated with conventional and atypical antipsy-chotics. J. Clin. Psychopharmacol. 25, 372-375.
9. Budney, A. J., Moore, B. A., Vandrey, R. G., and Hughes, J. R. (2003). The time course and significance of cannabis withdrawal. J. Abnorm. Psychol. 112, 393-402.
10. Chouinard, G., Ross-Chouinard, A., Annable, L., and Jones, B. (1980). The extrapyramidal symptom rating scale. Can. J. Neurol. Sci. 7, 233.
11. Conley, R. R., Kelly, D. L., and Gale, E. A. (1998). Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr. Res. 33, 95-101.
12. Cutler, A. J., Montgomery, S. A., Feifel, D., Lazarus, A., Aström, M., and Brecher, M. (2009). Extended release quetiap-ine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J. Clin. Psychiatry 70, 526-539.
13. Eaton, W. W., Martins, S. S., Nestadt, G., Bienvenu, O. J., Clarke, D., and Alexandre, P. (2008). The burden of mental disor-ders. Epidemiol. Rev. 30, 1-14.
14. El Manira, A., and Kyriakatos, A. (2010). The role of endocannabinoid sign-aling in motor control. Physiology (Bethesda) 25, 230-238.
15. Fabre, L. F. Jr., Arvanitis, L., Pultz, J., Jones, V. M., Malick, J. B., and Slotnick, V. B. (1995). ICI 204,636, a novel, atypi-cal antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophre-nia. Clin. Ther. 17, 366-378.
16. Falck, R. S., Wang, J., Carlson, R. G., and Siegal, H. A. (2006). Prevalence and correlates of current depressive symptomatology among a commu-nity sample of MDMA users in Ohio. Addict. Behav. 31, 90-101.
17. Green, A. I., Burgess, E. S., Dawson, R., Zimmet, S. V., and Strous, R. D. (2003). Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr. Res. 60, 81-85.
18. Harrison, I., Joyce, E. M., Mutsatsa, S. H., Hutton, S. B., Huddy, V., Kapasi, M., and Barnes, T. R. (2008). Naturalistic follow-up of co-morbid substance use in schizophrenia: the West London first-episode study. Psychol. Med. 38, 79-88.
19. Kampman, K. M., Pettinati, H. M., Lynch, K. G., Whittingham, T., Macfadden, W., Dackis, C., Tirado, C., Oslin, D. W., Sparkman, T., and O'Brien, C. P. (2007). A double-blind, placebo- controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism. J. Clin. Psychopharmacol. 27, 344-351.
20. Kay, S. R., Fiszbein, A., and Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizo-phrenia. Schizophr. Bull. 13, 261-276.
21. Koob, G. F., and Le Moal, M. (2001). Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24, 97-129.
22. Kouri, E. M., and Pope, H. G. Jr. (2000). Abstinence symptoms during with-drawal from chronic marijuana use. Exp. Clin. Psychopharmacol. 8, 483-492.
23. Lahmek, P., Berlin, I., Michel, L., Berghout, C., Meunier, N., and Aubin, H. J. (2009). Determinants of improvement in qual-ity of life of alcohol-dependent patients during an inpatient withdrawal pro-gramme. Int. J. Med. Sci. 6, 160-167.
24. Lapworth, K., Dawe, S., Davis, P., Kavanagh, D., Young, R., and Saunders, J. (2009). Impulsivity and positive psy-chotic symptoms influence hostility in methamphetamine users. Addict. Behav. 34, 380-385.
25. Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., Baldwin, R. M., Seibyl, J. P., Krystal, J. H., Charney, D. S., and Innis, R. B. (1996). Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizo-phrenic subjects. Proc. Natl. Acad. Sci. U.S.A. 93, 9235-9240.
26. Lee, K. U., Jeon, Y. W., Lee, H. K., and Jun, T. Y. (2009). Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia. Hum. Psychopharmacol. 24, 447-452.
27. Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S., Davis, S. M., Davis, C. E., Lebowitz, B. D., Severe, J., and Hsiao, J. K. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizo-phrenia. N. Engl. J. Med. 353, 1209-1223.
28. Littrell, K. H., Petty, R. G., Hilligoss, N. M., Peabody, C. D., and Johnson, C. G. (2001). Olanzapine treatment for patients with schizophrenia and substance abuse. J. Subst. Abuse Treat. 21, 217-221.
29. Lynskey, M. T., Glowinski, A. L., Todorov, A. A., Bucholz, K. K., Madden, P. A., and Nelson, E. C., Statham, D. J., Martin, N. G., Heath, A. C. (2004). Major depressive disorder, suicidal ideation, and suicide attempt in twins discordant for cannabis dependence and early-onset cannabis use. Arch. Gen. Psychiatry 61, 1026-1032.
30. Maat, A., Fouwels, A., and de Haan, L. (2008). Cocaine is a major risk fac-tor for antipsychotic induced aka-thisia, parkinsonism and dyskinesia. Psychopharmacol. Bull. 41, 5-10.
31. Martinotti, G., Andreoli, S., Di Nicola, M., Di Giannantonio, M., Sarchiapone, M., and Janiri, L. (2008). Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum. Psychopharmacol. 23, 417-424.
32. Martinotti, G., Di Nicola, M., Di Giannantonio, M., and Janiri, L. (2009). Aripiprazole in the treatment of patients with alcohol dependence: a double- blind, comparison trial vs. naltrexone. J. Psychopharmacol. 23, 123-129.
33. Martinotti, G., Di Nicola, M., and Janiri, L. (2007). Efficacy and safety of aripiprazole in alcohol dependence. Am. J. Drug Alcohol Abuse 33, 393-401.
34. Mathias, S., Lubman, D. I., and Hides, L. (2008). Substance-induced psycho-sis: a diagnostic conundrum. J. Clin. Psychiatry 69, 358-367.
35. Mauri, M. C., Volonteri, L. S., Fiorentini, A., Pirola, R., and Bareggi, S. R. (2007). Two weeks' quetiapine treatment for schizophrenia, drug-induced psy-chosis and borderline personality disorder: a naturalistic study with drug plasma levels. Expert Opin. Pharmacother. 8, 2207-2213.
36. Mueser, K. T., Drake, R. E., and Wallach, M. A. (1998). Dual diagnosis: a review of etiological theories. Addict. Behav. 23, 717-734.
37. Nakamura, M., Ogasa, M., Guarino, J., Phillips, D., Severs, J., Cucchiaro, J., and Loebel, A. (2009). Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J. Clin. Psychiatry 70, 829-836.
38. Negrete, J. C. (2003). Clinical aspects of substance abuse in persons with schiz-ophrenia. Can. J. Psychiatry 48, 14-21.
39. Patterson, T. L., Klapow, J. C., Eastham, J. H., Heaton, R. K., Evans, J. D., Koch, W. L., and Jeste, D. V. (1998). Correlates of functional status in older patients with schizophrenia. Psychiatry Res. 80, 41-52.
40. Potvin, S., Blanchet, P., and Stip, E. (2009). Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis. Schizophr. Res. 113, 181-188.
41. Potvin, S., Sepehry, A. A., and Stip, E. (2007). Meta-analysis of depressive symptoms in dual-diagnosis schizophrenia. Aust. N. Z. J. Psychiatry 41, 792-799.
42. Potvin, S., Stip, E., Lipp, O., Elie, R., Mancini- Marië, A., Demers, M. F., Roy, M. A., Bouchard, R. H., and Gendron, A. (2006a). Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr. Med. Res. Opin. 22, 1277-1285.
43. Potvin, S., Pampoulova, T., Mancini- Marie, A., Lipp, O., Bouchard, R. H., and Stip, E. (2006b). Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. J. Neurol. Neurosurg. Psychiatry 77, 796-798.
44. Pozzi, G., Martinotti, G., Reina, D., Dario, T., Frustaci, A., Janiri, L., and Bria, P. (2008). The assessment of post-detoxi-fication anhedonia: influence of clini-cal and psychosocial variables. Subst. Use Misuse 43, 722-732.
45. Regier, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L., and Goodwin, F. K. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264, 2511-2518.
46. Rizkallah, E., Stip, E., Zhornitsky, S., Pampoulova, T., Gendron, A., Rompre, P. P., Chiasson, J. P., and Potvin, S. (2010). Clinical evolution of patients with substance use disorders during treatment with quetiapine: a 12-week, open-label, naturalistic trial. Expert Opin. Pharmacother. 11, 2947-2951.
47. Rosenthal, R. N., Perkel, C., Singh, P., Anand, O., and Miner, C. R. (1998). A pilot open randomized trial of val-proate and phenobarbital in the treat-ment of acute alcohol withdrawal. Am. J. Addict. 7, 189-197.
48. Sobell, L. C., and Sobell, M. B. (1992). " Timeline follow-back: a technique for assessing self-reported ethanol consumption," in Measuring Alcohol Consumption: Psychosocial and Biological Methods, eds J. Allen and R. Z. Litten (Totowa, NJ: Humana Press), 41-72.
49. Swartz, M. S., Wagner, H. R., Swanson, J. W., Stroup, T. S., McEvoy, J. P., Reimherr, F., Miller, D. D., McGee, M., Khan, A., Canive, J. M., Davis, S. M., Hsiao, J. K., and Lieberman, J. A. (2008). The effec-tiveness of antipsychotic medications in patients who use or avoid illicit sub-stances: results from the CATIE study. Schizophr. Res. 100, 39-52.
50. Turkington, A., Mulholland, C. C., Rushe, T. M., Anderson, R., McCaul, R., Barrett, S. L., Barr, R. S., and Cooper, S. J. (2009). Impact of persistent sub-stance misuse on 1-year outcome in first-episode psychosis. Br. J. Psychiatry 195, 242-248.
51. Unnithan, S. B., and Cutting, J. C. (1992). The cocaine experience: refuting the concept of a model psychosis? Psychopathology 25, 71-78.
52. van Nimwegen, L. J., de Haan, L., van Beveren, N. J., van der Helm, M., van den Brink, W., and Linszen, D. (2008). Effect of olanzapine and risp-eridone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. Can. J. Psychiatry 53, 400-405.
53. Villalta-Gil, V., Vilaplana, M., Ochoa, S., Haro, J. M., Dolz, M., Usall, J., Cervilla, J., and NEDENA Group. (2006). Neurocognitive performance and negative symptoms: are they equal in explaining disability in schizophre-nia outpatients? Schizophr. Res. 87, 246-253.
54. Volkow, N. D., Fowler, J. S., Wang, G. J., and Swanson, J. M. (2004). Dopamine in drug abuse and addiction: results from imaging studies and treatment impli-cations. Mol. Psychiatry 9, 557-569.
55. Weiden, P. J. (2007). EPS profiles: the atypical antipsychotics are not all the same. J. Psychiatr. Pract. 13, 13-24.
56. West, R., and Gossop, M. (1994). Overview: a comparison of withdrawal symptoms from different drug classes. Addiction 89, 1483-1489.
57. Zhornitsky, S., Potvin, S., Moteshafi, H., Dubreucq, S., Rompre, P. P., and Stip, E. (2011). Dose-response and comparative efficacy and toler-ability of quetiapine across psychi-atric disorders: a systematic review of the placebo-controlled mono-therapy and add-on trials. Int. Clin. Psychopharmacol. [Epub ahead of print].
58. Zhornitsky, S., Stip, E., Pampoulova, T., Rizkallah, E., Lipp, O., Bentaleb, L. A., Chiasson, J. P., and Potvin, S. (2010a). Extrapyramidal symptoms in substance abusers with and with-out schizophrenia and in nonabusing patients with schizophrenia. Mov. Disord. 25, 2188-2194.
59. Zhornitsky, S., Rizkallah, E., Pampoulova, T., Chiasson, J. P., Stip, E., Rompré, P. P., and Potvin, S. (2010b). Antipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis. J. Clin. Psychopharmacol. 30, 417-424.
60. Ziedonis, D. M., Smelson, D., Rosenthal, R. N., Batki, S. L., Green, A. I., Henry, R. J., Montoya, I., Parks, J., and Weiss, R. D. (2005). Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J. Psychiatr. Pract. 11, 315-339.